DiaMedica Therapeutics Inc.
DMAC evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Market Cap:
- $348.9M
- Lead Asset:
- dm300 (Phase 2/Phase 3)
What it means
What to watch
Prepared research question
What matters most for DMAC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DMAC
DiaMedica Therapeutics Inc. (DMAC) is a clinical-stage biotech company developing DM199, a recombinant human KLK1 protein, for acute ischemic stroke, preeclampsia, and early-onset fetal growth restriction.
Key risk: Funding dependency
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$348.9M
Cash Runway
—
Lead Asset
dm300 (Phase 2/Phase 3)
Next Catalyst
—
Tracking 1 pipeline candidate for DiaMedica Therapeutics Inc..
DiaMedica Therapeutics Inc. (DMAC) is a clinical-stage biotech company developing DM199, a recombinant human KLK1 protein, for acute ischemic stroke, preeclampsia, and early-onset fetal growth restriction.
- DM199 is being evaluated in the ReMEDy2 Phase 2/3 trial for acute ischemic stroke and in a global Phase 2 trial for early-onset preeclampsia [sec_mda · as of 2026-08-10].
- The company reported statistically significant blood pressure reductions in late-onset preeclampsia [news · published 2026-08-11].
- Cash runway is expected to extend through 2027 [news · published 2026-08-11].
- In July 2025, DiaMedica completed a private placement with net proceeds of $30.0 million [sec_mda · as of 2025-11-12].
- The company expects current cash resources to fund planned operations for at least the next twelve months from the date of the condensed consolidated financial statements included in the report [sec_mda · as of 2026-08-10].
What works
- DM199 has shown statistically significant blood pressure reductions in late-onset preeclampsia, supporting its potential in a large unmet-need indication [news · published 2026-08-11].
- The company maintains a cash runway through 2027, providing a multi-year operational horizon for ongoing trials [news · published 2026-08-11].
- DiaMedica is advancing DM199 across multiple indications (stroke, preeclampsia, FGR), diversifying its pipeline [news · published 2026-08-11].
What to weigh
- The company expects to need substantial additional capital to complete R&D activities and bring DM199 to a point where it can be out-licensed or sold [sec_mda · as of 2025-11-12].
- Future negative quarterly cash flows are expected to increase moderately as clinical activities expand [sec_mda · as of 2026-08-10].
- There is no assurance that additional funding will be obtained on favorable terms or at all [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
Cash runway through 2027
“DMAC reports statistically significant blood pressure reductions in late-onset preeclampsia, progresses FGR study, and maintains cash runway through 2027 despite increased R&D spending.”
News · August 11, 2026
Need for substantial additional capital
“notwithstanding the completion of our July 2025 private placement in which we received net proceeds of $30.0 million, we expect we will need substantial additional capital to complete our R&D activities, including current and anticipated future clinical studies, regulatory activities, and otherwise develop our product candidate, DM199, or any future product candidate, to a point”
SEC MD&A · November 12, 2025
Cash sufficient for at least twelve months
“We expect our current cash resources to be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of the condensed consolidated financial statements included in this report.”
SEC MD&A · August 10, 2026
Statistically significant blood pressure reductions in late-onset preeclampsia
“DMAC reports statistically significant blood pressure reductions in late-onset preeclampsia”
News · August 11, 2026
Risks & what to watch (3)›
Key risks
- Funding dependency — The company expects to need substantial additional capital to complete R&D; no assurance of favorable terms [sec_mda · as of 2025-11-12].
- Increasing cash burn — Negative quarterly cash flows expected to increase moderately as clinical activities expand [sec_mda · as of 2026-08-10].
- No commercial revenue — DM199 has not yet been out-licensed or commercially sold; all operations are pre-revenue [sec_mda · as of 2026-08-10].
What to watch
- Enrollment and interim data from the ReMEDy2 Phase 2/3 acute ischemic stroke trial [sec_mda · as of 2026-08-10].
- Initiation and early results of the global Phase 2 preeclampsia trial in early-onset patients [sec_mda · as of 2026-08-10].
- Progress in the early-onset fetal growth restriction (FGR) study [news · published 2026-08-11].
- Any future financing events or partnerships to address the expected need for additional capital [sec_mda · as of 2025-11-12].
Sources: News · SEC MD&A · Generated October 1, 2026 · How we verify sources →
Run DiaMedica Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available DiaMedica Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2/Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
98
Total value held
$79.0M
| Holder | Shares | Value |
|---|---|---|
| cooperman leon g | 2,020,000 | $13.7M |
| blackrock, inc. | 1,856,187 | $12.6M |
| millennium management llc | 935,592 | $6.3M |
| paragon associates & paragon associates ii joint venture | 875,000 | $5.9M |
| geode capital management, llc | 780,516 | $5.3M |
| state street corp | 644,211 | $4.4M |
| first manhattan co. llc. | 455,000 | $3.1M |
| bleichroeder lp | 382,317 | $2.6M |
| northern trust corp | 338,526 | $2.3M |
| vanguard capital management llc | 333,456 | $2.3M |
Showing top 10 of 98 institutional holders of DiaMedica Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 13.6%
- Days to cover
- 26.3
- Shares short
- 4,899,610
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DMAC short interestGovernance
Frequently asked questions
What is the AI investment thesis for DiaMedica Therapeutics Inc.?
DiaMedica Therapeutics Inc. (DMAC) is a clinical-stage biotech company developing DM199, a recombinant human KLK1 protein, for acute ischemic stroke, preeclampsia, and early-onset fetal growth restriction.
What is DiaMedica Therapeutics Inc.'s lead drug candidate?
DiaMedica Therapeutics Inc.'s most advanced tracked candidate is dm300 (Phase 2/Phase 3) for Severe acute pancreatitis.
Who is the CEO of DiaMedica Therapeutics Inc.?
Mr. Dietrich John Pauls MBA is the chief executive officer of DiaMedica Therapeutics Inc. (DMAC).
Where is DiaMedica Therapeutics Inc. headquartered?
DiaMedica Therapeutics Inc. (DMAC) is headquartered in Minneapolis, MN, United States.
What therapeutic areas does DiaMedica Therapeutics Inc. focus on?
DiaMedica Therapeutics Inc. develops therapies across Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.